Ensign Peak Advisors’s Celldex Therapeutics CLDX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $490K | Hold |
24,078
| – | – | ﹤0.01% | 1558 |
|
|
2025
Q1 | $437K | Buy |
24,078
+650
| +3% | +$11.8K | ﹤0.01% | 1581 |
|
|
2024
Q4 | $592K | Hold |
23,428
| – | – | ﹤0.01% | 1553 |
|
|
2024
Q3 | $796K | Hold |
23,428
| – | – | ﹤0.01% | 1444 |
|
|
2024
Q2 | $867K | Sell |
23,428
-155,001
| -87% | -$5.74M | ﹤0.01% | 1373 |
|
|
2024
Q1 | $7.49M | Sell |
178,429
-1,182
| -0.7% | -$49.6K | 0.01% | 524 |
|
|
2023
Q4 | $7.12M | Buy |
179,611
+87,482
| +95% | +$3.47M | 0.01% | 534 |
|
|
2023
Q3 | $2.54M | Hold |
92,129
| – | – | 0.01% | 760 |
|
|
2023
Q2 | $3.13M | Hold |
92,129
| – | – | 0.01% | 726 |
|
|
2023
Q1 | $3.31M | Hold |
92,129
| – | – | 0.01% | 678 |
|
|
2022
Q4 | $4.11M | Buy |
92,129
+81,419
| +760% | +$3.63M | 0.01% | 607 |
|
|
2022
Q3 | $301K | Hold |
10,710
| – | – | ﹤0.01% | 1706 |
|
|
2022
Q2 | $289K | Hold |
10,710
| – | – | ﹤0.01% | 1694 |
|
|
2022
Q1 | $365K | Hold |
10,710
| – | – | ﹤0.01% | 1682 |
|
|
2021
Q4 | $414K | Buy |
+10,710
| New | +$414K | ﹤0.01% | 1690 |
|